AGREEMENT TO AMEND SERIES A-1 CONVERTIBLE PREFERREDOutlook Therapeutics, Inc. • January 31st, 2020 • Biological products, (no disgnostic substances) • New York
This agreement to amend the Certificate of Designations (“COD”) setting forth the terms of the Series A-1 Convertible Preferred Stock, par value $0.01 per share (the “Series A-1 Preferred”) (this “Agreement”) of Outlook Therapeutics, Inc. (formerly known as Oncobiologics, Inc., the “Company”), dated as of January 27, 2020, by and between the Company and BioLexis Pte. Ltd. (formerly known as GMS Tenshi Holdings Pte. Limited, and together with or any of its permitted assigns, the “Holder”). Capitalized terms used and not otherwise defined herein shall have the respective meanings ascribed to such terms in the COD (as defined below), whether defined therein or incorporated by reference.
TERMINATION AGREEMENT AND MUTUAL RELEASETermination Agreement and Mutual Release • January 31st, 2020 • Outlook Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Termination Agreement and Mutual Release (“Termination Agreement”) is made and entered into as of this 27 day of January, 2020 (the “Execution Date”), and effective as of the Termination Date, by and between Outlook Therapeutics, Inc., a Delaware corporation with a principal place of business at 7 Clarke Drive, Cranbury, New Jersey 08512 (“Outlook”) and MTTR LLC, a Delaware limited liability company with a principal place of business at 19259 Braemore Rd., Porter Ranch, California 91326 (“MTTR”). Each of Outlook and MTTR shall hereinafter be referred to as a “Party” and collectively as the “Parties”.
